Roche’s Soliris rival satralizumab scores in phase 3 study

Alexion also received European Commission approval for the extended use of Soliris in the same indication in August. ... However, both Roche and Alexion could face competition from biosimilars, as Amgen  recently filed a patent infringement action

US, EU regulators start review of Roche’s Soliris rival satralizumab

paralysis. At the moment the only approved treatment in the US is Alexion’s complement C5 inhibitor  Soliris (eculizumab), which got a green light from the FDA in June, and there ... Viela thinks inebilizumab has a dosing advantage over both Soliris

Alexion eyes Soliris combo with $930m deal to buy Achillion

paroxysmal nocturnal haemoglobinuria (PNH), a rare disease whose treatment is currently dominated by Alexion’s blockbuster complement C5 inhibitor  Soliris (eculizumab). ... combination with Soliris in PNH – and follow-up ACH-5228 in phase 1.

Roche presents new data in NMOSD, could challenge Alexion's Soliris

Reduced risk of relapse by 55%. Roche has presented new data on satralizumab for neuromyelitis optica spectrum disorder (NMOSD),  setting it up for a potential market battle with Alexion’s Soliris. ... progression. Alexion’s Soliris received FDA

1 2 3 4 5 6 7 8 9 [ Next 5 results ]